Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel, branded as ENCELTO. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurodegenerative eye disorder that leads to vision loss. This approval paves the way for Neurotech’s commercial entry into the MacTel therapeutics market.
MacTel is a neurodegenerative retinal disease in adults that leads to progressive and irreversible vision loss, significantly affecting patients' quality of life. Macular telangiectasia type 2, also known as...
